Search results
Results From The WOW.Com Content Network
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.
Lead time bias happens when survival time appears longer because diagnosis was done earlier (for instance, by screening), irrespective of whether the patient lived longer. Lead time is the duration of time between the detection of a disease (by screening or based on new experimental criteria) and its usual clinical presentation and diagnosis ...
Proliferation, as one of the hallmarks and most fundamental biological processes in tumors, [1] is associated with tumor progression, response to therapy, and cancer patient survival. [2] Consequently, the evaluation of a tumor proliferative index (or growth fraction) has clinical significance in characterizing many solid tumors and hematologic ...
Prognosis (Greek: πρόγνωσις "fore-knowing, foreseeing"; pl.: prognoses) is a medical term for predicting the likelihood or expected development of a disease, including whether the signs and symptoms will improve or worsen (and how quickly) or remain stable over time; expectations of quality of life, such as the ability to carry out daily activities; the potential for complications and ...
Survival rate is a part of survival analysis. It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy. The survival period is usually reckoned from date of ...
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
Length time bias in cancer screening. Screening appears to lead to better survival even when actually no one lived any longer. Length time bias (or length bias) is an overestimation of survival duration due to the relative excess of cases detected that are asymptomatically slowly progressing, while fast progressing cases are detected after giving symptoms.
Metabolites are potentially useful for predicting treatment response since they are the endpoint of many molecular pathways. [10] For example, Sreekumar et al reported that the level of sarcosine, which is a derivative of glycine, in the urine of men is correlated with metastasis of prostate cancer .